Critical Survey: ProMetic Life Sciences (OTCMKTS:PFSCF) & Ampio Pharmaceuticals (NYSE:AMPE)

Risk and Volatility

Ampio Pharmaceuticals has a beta of 5.96, suggesting that its share price is 496% more volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500.

Profitability

This table compares Ampio Pharmaceuticals and ProMetic Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%

Earnings and Valuation

This table compares Ampio Pharmaceuticals and ProMetic Life Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.02
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A

Ampio Pharmaceuticals has higher earnings, but lower revenue than ProMetic Life Sciences.

Institutional & Insider Ownership

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Ampio Pharmaceuticals beats ProMetic Life Sciences on 7 of the 8 factors compared between the two stocks.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.